Final report on testing results for SARS-CoV-2 virus and SARS-CoV-2 antibodies

TASK 22 Testing study participants for SARSCoV2 virus M1M18 Roche Risch Risch servicesDuring the cohort study positive signals that are generated by the algorithm developed in WP1 will be followed up by molecular SARSCoV2 testing In the Netherlands anyone with respiratory symptoms can be tested freeofcharge for the SARSCoV2 virus as of 1 June 2020 The government aims to provide a test result within 24 hours and anyone who tests positive is automatically transferred to the public contacttracing programme We will therefore evaluate the possibility of asking study participants with a positive signal to attend the nearest public testing site and to share the testing information with the study team Some participants may not have access to public testing for example because they do not have overt symptoms and these participants will be tested by the study team In the Principality of Liechtenstein people with symptoms of COVID19 are recommended to be tested by a COVID19 RTPCR assay This test is covered by mandatory health insurance In addition individuals without symptoms wanting to be tested can also get an RTPCR test on their own cost The Liechtenstein RTPCR testing is done in a central lab labormedizinisches zentrum Dr Risch which is accredited according to ISO 17025 The laboratory is officially recognized by the Liechtenstein and Swiss office of Public Health for testing of SARSCoV2 virus and represents one of the Swiss testing labs accomplishing the highest test volumes Study participants are asked to get tested as soon as they have symptoms compatible with COVID19 For this purpose they can consult the national drivethrough testing site their family physician or the emergency room of the national hospital Should participants use testing abroad they will be asked to provide the result Alternatively the study team contacts the national office of Public Health which knows all the cases of notifiable diseases including COVID19 The COVIGAPP study is run by the study team of the national laboratory running almost all COVID19 tests in the country RTPCR testing for SARSCoV2 is done using the Roche cobas SARSCoV2 Test designed for use on the cobas 6800 or cobas 8800 instruments These instruments are available at the central laboratory of the Dutch blood bank Sanquin and other locations including the labormedizinisches zentrum Dr Risch in Buchs Switzerland The test is a singlewell dual target assay which includes both specific detection of SARSCoV2 and of the sarbecovirus subgenus family that includes SARSCoV2 Roche has committed 60008000 SARSCoV2 tests to this study This capacity may not be needed given the fact that we will possibly refer most participants to public testing sites in which case we will test a subset of participants for additional respiratory pathogens such as influenza and RSV The signs and symptoms caused by these pathogens are similar to those caused by COVID19 and this additional testing will improve our ability to determine the WP1 algorithms specificity The participants selected for this substudy will attend a public testing site but in addition they will selfcollect a nasopharyngeal swab at home and store it in a freezer until transport to the laboratory If possible samples could be analysed for several respiratory pathogens using the Roche platform TASK 23 Testing study participants for SARSCoV2 antibodies M10M18 Sanquin RischAll 30000 participants in the Dutch cohort study will provide a finger prick blood sample which they can do at home at their baseline visit and at the end of their followup period endline All endline samples will be tested for SARSCoV2 antibodies using an inhouse ELISA method in the central laboratory of Sanquin Stored baseline samples of participants who have a positive ELISA at endline will also be tested to determine whether the participant was alr